Lung Cancer Trials Ask AI to find trials
CompletedPhase 2NCT00047840
Official study title

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Study summary

The purpose of this study is to assess the efficacy and safety of ZD6474 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedZD6474 and Placebo

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Locally advanced · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 25, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?26 U.S. locations

Locations may change over time.

Who runs it?Genzyme, a Sanofi Company

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Genzyme, a Sanofi Company
Interventions being studied
Drug: ZD6474; Drug: Placebo; Drug: Docetaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Locally advanced→Metastatic or stage IV→
Treatment approach
Chemotherapy→
Study topics
After prior treatment→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologic or cytologic confirmation of NSCLC (locally advanced or metastatic, IB-IV)
  • Failure of first-line platinum-based chemotherapy
Reasons someone may not be able to joinExclusion criteria
  • Mixed small cell or non-small-cell histology
  • Bronchoalveolar carcinoma
  • Prior chemotherapy or herbal preparations must be discontinued more than 4 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin and suramin)
  • Prior treatment with docetaxel

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Research SiteLos Angeles, California
  • Research SiteJacksonville, Florida
  • Research SiteAtlanta, Georgia
  • Research SiteNew Orleans, Louisiana
  • Research SiteBoston, Massachusetts
  • Research SitePittsfield, Massachusetts
  • Research SiteAnn Arbor, Michigan
  • Research SiteDetroit, Michigan
  • Research SiteBillings, Montana
  • Research SiteGreat Neck, New York
  • Research SiteNew York, New York
  • Research SiteDurham, North Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 25, 2016. Always confirm current availability with the study team.

View original record ↗